Diseases [C] » Immune System Diseases [C20] » Hypersensitivity » Hypersensitivity, Delayed » Sarcoidosis » Sarcoidosis, Pulmonary
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Interstitial » Sarcoidosis, Pulmonary
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Sarcoidosis » Sarcoidosis, Pulmonary
Description
Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431) MeSH
Hierarchy View
Phase 4 Indicated Drugs (5)
Phase 3 Indicated Drugs (5)
Phase 1 Indicated Drugs (4)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (11)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
